Maurer, HH; Kraemer, T; Springer, D; Staack, RF. Chemistry, pharmacology, toxicology, and hepatic metabolism of designer drugs of the amphetamine (Ecstasy), piperazine, and pyrrolidinophenone types. A synopsis. Ther. Drug Monit., 1 Apr 2004, 26 (2), 127–131. 121 kB.
Iversen, LL. Consideration of the cathinones, Advisory Council on the Misuse of Drugs, 31 Mar 2010. 286 kB.
Staack, RF; Maurer, HH. Metabolism of designer drugs of abuse. Curr. Drug Metab., 1 Jun 2005, 6 (3), 259–274. 104 kB. https://doi.org/10.2174/1389200054021825 #PPP, 1 (Fig. 6)
Reitzel, LA; Dalsgaard, PW; Müller, IB; Cornett, C. Identification of ten new designer drugs by GC-MS, UPLC-QTOF-MS, and NMR as part of a police investigation of a Danish Internet company. Drug Test. Anal., 1 May 2012, 4 (5), 342–354. 1.2 MB. https://doi.org/10.1002/dta.358 #PPP GC,LC,MS,NMR
Rõsner, P; Junge, T; Fritschi, G; Klein, B; Thielert, K; Kozlowski, M. Neue synthetische Drogen: Piperazin-, propicyclidin- und α-aminopropiophenonderivate. Toxichem Krimtech, 1 Jan 1999, 66 (2), 81–90. 1.2 MB. #3 MS,NMR,IR
Glennon, RA. Bath salts, mephedrone, and methylenedioxypyrovalerone as emerging illicit drugs that will need targeted therapeutic intervention. Adv. Pharmacol., 1 Jan 2014, 69, 581–620. 564 kB. https://doi.org/10.1016/B978-0-12-420118-7.00015-9
Fornal, E. Study of collision-induced dissociation of electrospray-generated protonated cathinones. Drug Test. Anal., 1 Jul 2014, 6 (7-8), 705-715. 527 kB. https://doi.org/10.1002/dta.1573 #20
Gaspar, H; Bronze, S; Oliveira, C; Victor, BL; Machuqueiro, M; Pacheco, R; Caldeira, MJ; Santos, S. Proactive response to tackle the threat of emerging drugs: Synthesis and toxicity evaluation of new cathinones. Forensic Sci. Int., 1 Sep 2018, 290, 146–156. 1.6 MB. https://doi.org/10.1016/j.forsciint.2018.07.001 #PPP MS,NMR
EMCDDA. New drugs in Europe, 2009, European Monitoring Centre for Drugs and Drug Addiction, Lisbon, 1 May 2010. 321 kB. #2
Baumann, MH; Walters, HM; Niello, M; Sitte, HH. Neuropharmacology of synthetic cathinones. In New Psychoactive Substances: Pharmacology, Clinical, Forensic and Analytical Toxicology; Maurer, HH; Brandt, SD, Eds., Springer, Berlin, Heidelberg, 1 Jan 2018; pp 113–142. 409 kB. https://doi.org/10.1007/164_2018_178 #α-PPP
Bork, W; Dahlenburg, R; Gimbel, M; Jacobsen-Bauer, A; Zörntlein, S. Herleitung Von Grenzwerten Der „nicht Geringen Menge“ Im Sinne Des Btmg. Toxichem Krimtech, 1 Jan 2019, 86 (1), 5–91. 4.4 MB. #CA-013
Kolanos, R; Sakloth, F; Jain, AD; Partilla, JS; Baumann, MH; Glennon, RA. Structural modification of the designer stimulant α-pyrrolidinovalerophenone (α-PVP) influences potency at dopamine transporters. ACS Chem. Neurosci., 21 Oct 2015, 6 (10), 1726–1731. 767 kB. https://doi.org/10.1021/acschemneuro.5b00160 #9 NMR,other
Gatch, MB; Forster, MJ. Methylenedioxymethamphetamine-like discriminative stimulus effects of pyrrolidinyl cathinones in rats. J. Psychopharmacol., 1 Jul 2020, 34 (7), 778-785. 546 kB. https://doi.org/10.1177/0269881120914213 #α-PPP
Chen, Y; Canal, CE. Structure–activity relationship study of psychostimulant synthetic cathinones reveals nanomolar antagonist potency of α-pyrrolidinohexiophenone at human muscarinic M2 receptors. ACS Chem. Neurosci., 18 Mar 2020, 11 (6), 960–968. 1.2 MB. https://doi.org/10.1021/acschemneuro.0c00008 #α-PPP
Hägele, JS; Basrak, M; Schmid, MG. Enantioselective separation of novel psychoactive substances using a Lux® AMP 3 μm column and HPLC-UV. J. Pharm. Biomed. Anal., 5 Feb 2020, 179, 112967. 3.6 MB. https://doi.org/10.1016/j.jpba.2019.112967 #V0 LC